According to reports, the Union Cabinet decided to not discuss the National Pharmaceutical Pricing Policy (NPPP) in a recent meeting due to concerns over the NPPP’s price-fixing mechanism policy. The finance ministry raised concerns over the NPPP, and, as a result, the delay in discussion threatens to prevent the NPPP from being finalized and submitted to the Supreme Court by its given deadline of November 25. A group of ministers had originally suggested the price-fixing mechanism, though the finance ministry has found loopholes in its legislature.
Featured News
Oregon Just Passed the Country’s Toughest Chatbot Law. Your Company May Already Be Breaking It.
Mar 23, 2026 by
CPI
Newsmax, DirecTV Join Challenge to FCC’s Nexstar-Tegna Decision
Mar 23, 2026 by
CPI
House Committee Readies Hearing on Tokenized Securities Trading Rules
Mar 23, 2026 by
CPI
Vinson & Elkins Launches Brussels Office With Hire of Hogan Lovells Antitrust Partner
Mar 23, 2026 by
CPI
Italy’s Competition Watchdog Penalizes Trustpilot Over Consumer Review System
Mar 23, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Data-Driven Competition
Mar 19, 2026 by
CPI
Data-Driven Competition: Implications For Enforcement and Merger Control
Mar 19, 2026 by
Alexandre de Corniere & Greg Taylor
From Tipping to Trustees: Why Data-Driven Markets Require Institutional Design, Not Optimization
Mar 19, 2026 by
Jens Prüfer & Paul de Bijl
Data Barriers to Entry: What We’ve Learned About Spotting Them and What We Still Don’t Know About Solutions
Mar 19, 2026 by
Bruno Carballa-Smichowski
When the Perfect Is the Enemy of the Good: Price Discrimination, Affordability, Precarity and Market Dynamism
Mar 19, 2026 by
Dan Ciuriak